Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cellectis S-A stock | $10.83

Learn how to easily invest in Cellectis S-A stock.

Cellectis S.A is a biotechnology business based in the US. Cellectis S-A shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectis S-A employs 272 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cellectis S-A

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLLS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cellectis S-A stock price (NASDAQ: CLLS)

Use our graph to track the performance of CLLS stocks over time.

Cellectis S-A shares at a glance

Information last updated 2021-10-16.
Latest market close$10.83
52-week range$9.10 - $34.71
50-day moving average $13.04
200-day moving average $15.03
Wall St. target price$26.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.78

Buy Cellectis S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cellectis S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellectis S-A price performance over time

Historical closes compared with the close of $10.83 from 2021-10-15

1 week (2021-10-07) N/A
1 month (2021-09-17) -24.95%
3 months (2021-07-16) -23.46%
6 months (2021-04-16) -44.18%
1 year (2020-10-16) -44.97%
2 years (2019-10-18) 6.70%
3 years (2018-10-18) 26.97
5 years (2016-10-18) 19.55

Cellectis S-A financials

Revenue TTM $70.1 million
Gross profit TTM $46.2 million
Return on assets TTM -16.46%
Return on equity TTM -41.75%
Profit margin -172.22%
Book value $6.07
Market capitalisation $493.8 million

TTM: trailing 12 months

Shorting Cellectis S-A shares

There are currently 1.3 million Cellectis S-A shares held short by investors – that's known as Cellectis S-A's "short interest". This figure is 1.6% down from 1.3 million last month.

There are a few different ways that this level of interest in shorting Cellectis S-A shares can be evaluated.

Cellectis S-A's "short interest ratio" (SIR)

Cellectis S-A's "short interest ratio" (SIR) is the quantity of Cellectis S-A shares currently shorted divided by the average quantity of Cellectis S-A shares traded daily (recently around 107925.19413287). Cellectis S-A's SIR currently stands at 11.59. In other words for every 100,000 Cellectis S-A shares traded daily on the market, roughly 11590 shares are currently held short.

However Cellectis S-A's short interest can also be evaluated against the total number of Cellectis S-A shares, or, against the total number of tradable Cellectis S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellectis S-A's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cellectis S-A shares in existence, roughly 30 shares are currently held short) or 0.0409% of the tradable shares (for every 100,000 tradable Cellectis S-A shares, roughly 41 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cellectis S-A.

Find out more about how you can short Cellectis S-A stock.

Cellectis S-A share dividends

We're not expecting Cellectis S-A to pay a dividend over the next 12 months.

Cellectis S-A share price volatility

Over the last 12 months, Cellectis S-A's shares have ranged in value from as little as $9.1 up to $34.71. A popular way to gauge a stock's volatility is its "beta".

CLLS.US volatility(beta: 2.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis S-A's is 2.2206. This would suggest that Cellectis S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cellectis S-A overview

Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat.

Frequently asked questions

What percentage of Cellectis S-A is owned by institutions?
Currently 39.288% of Cellectis S-A shares are held by institutions.
How many people work for Cellectis S-A?
Latest data suggests 272 work at Cellectis S-A.
When does the fiscal year end for Cellectis S-A?
Cellectis S-A's fiscal year ends in December.
Where is Cellectis S-A based?
Cellectis S-A's address is: 8, rue de la Croix Jarry, Paris, France, 75013
What is Cellectis S-A's ISIN number?
Cellectis S-A's international securities identification number is: US15117K1034
What is Cellectis S-A's CUSIP number?
Cellectis S-A's Committee on Uniform Securities Identification Procedures number is: 15117K103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site